FDA approval of AstraZeneca lupus drug sets up competition w

FDA approval of AstraZeneca lupus drug sets up competition with GSK's Benlysta


MedCity News
FDA approval of AstraZeneca lupus drug sets up competition with GSK’s Benlysta
An AstraZeneca lupus drug has been awarded FDA approval for treating the most common form of the autoimmune disorder. The regulatory decision gives AstraZeneca a product that can compete head-to-head with GlaxoSmithKline’s lupus drug, Benlysta.
Shares0
 
Patients who suffer from the most common form of lupus have a new treatment option, an AstraZeneca drug that is now the first new therapy for the autoimmune disorder since a GlaxoSmithKline medicine cleared the regulatory bar a decade ago.
FDA approval of the AstraZeneca drug, anifrolumab, covers adults with moderate to severe systemic lupus erythematosus who are also receiving standard treatment that includes anti-inflammatory and immunosuppressing medications. AstraZeneca will market its new drug under the name “Saphnelo.”

Related Keywords

United States , America , American , , Glaxosmithkline , Astrazeneca , Lupus Foundation Of America , Lupus Foundation , ஒன்றுபட்டது மாநிலங்களில் , அமெரிக்கா , அமெரிக்கன் , கிளாக்சோஸ்மித்க்லைன் , லூபஸ் அடித்தளம் ஆஃப் அமெரிக்கா , லூபஸ் அடித்தளம் ,

© 2025 Vimarsana